VICTORIA, September 28, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, ImmunoPrecise’s Chief Executive Officer, will present an overview of the company at the Gravitas Healthcare Investor Day on Thursday, October 1st at 11:00 AM EST.
This year’s Gravitas Healthcare Investor Day will feature several leaders in healthcare and will be attended virtually by institutional and retail investors from North America and abroad. For additional details about the conference and Gravitas Securities Inc., please visit: www.gravitassecurities.com.
Event: Gravitas Healthcare Investor Day (virtual)
Date: Thursday, October 1st
Time: 9:00 AM – 5:30 PM EST
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise’s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact email@example.com.
For investor relations please contact: Frederick Chabot, Phone: 1-438-863-7071, Email: firstname.lastname@example.org, Contact Financial Corp., Suite 810, 609 Granville Street, P.O. Box 10322, Vancouver, B.C., V7Y 1G5, Canada.
Source: ImmunoPrecise Antibodies Ltd.